FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281570368> ?p ?o ?g. }

• W4281570368 abstract "Objective: Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion), an oral N-methyl-D-aspartate (NMDA) receptor antagonist and σ1 receptor agonist, in the treatment of major depressive disorder (MDD).Methods: This double-blind, phase 3 trial, was conducted between June 2019 and December 2019. Patients with a DSM-5 diagnosis of MDD were randomized in a 1:1 ratio to receive dextromethorphan-bupropion (45 mg-105 mg tablet) or placebo, orally (once daily for days 1-3, twice daily thereafter) for 6 weeks. The primary endpoint was the change from baseline to week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Other efficacy endpoints and variables included MADRS changes from baseline at week 1 and 2, clinical remission (MADRS score ≤ 10), clinical response (≥ 50% reduction in MADRS score from baseline), clinician- and patient-rated global assessments, Quick Inventory of Depressive Symptomatology-Self-Rated, Sheehan Disability Scale, and quality of life measures.Results: A total of 327 patients were randomized: 163 patients to dextromethorphan-bupropion and 164 patients to placebo. Mean baseline MADRS total scores were 33.6 and 33.2 in the dextromethorphan-bupropion and placebo groups, respectively. The least-squares mean change from baseline to week 6 in MADRS total score was -15.9 points in the dextromethorphan-bupropion group and -12.0 points in the placebo group (least-squares mean difference, -3.87; 95% confidence interval [CI], -1.39 to -6.36; P = .002). Dextromethorphan-bupropion was superior to placebo for MADRS improvement at all time points including week 1 (P = .007) and week 2 (P < .001). Remission was achieved by 39.5% of patients with dextromethorphan-bupropion versus 17.3% with placebo (treatment difference, 22.2; 95% CI, 11.7 to 32.7; P < .001), and clinical response by 54.0% versus 34.0%, respectively (treatment difference, 20.0%; 95% CI, 8.4%, 31.6%; P < .001), at week 6. Results for most secondary endpoints were significantly better with dextromethorphan-bupropion than with placebo at almost all time points (eg, CGI-S least-squares mean difference at week 6, -0.48; 95% CI, -0.48 to -0.79; P = .002). The most common adverse events in the dextromethorphan-bupropion group were dizziness, nausea, headache, somnolence, and dry mouth. Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or increased sexual dysfunction.Conclusions: In this phase 3 trial in patients with MDD, treatment with dextromethorphan-bupropion (AXS-05) resulted in significant improvements in depressive symptoms compared to placebo starting 1 week after treatment initiation and was generally well tolerated.Trial Registration: ClinicalTrials.gov Identifier: NCT04019704." @default.
• W4281570368 created "2022-05-27" @default.
• W4281570368 creator A5009671318 @default.
• W4281570368 creator A5045156395 @default.
• W4281570368 creator A5048498728 @default.
• W4281570368 creator A5065878511 @default.
• W4281570368 creator A5073345392 @default.
• W4281570368 creator A5080797609 @default.
• W4281570368 creator A5084024326 @default.
• W4281570368 date "2022-05-30" @default.
• W4281570368 modified "2023-10-13" @default.
• W4281570368 title "Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder" @default.
• W4281570368 doi "https://doi.org/10.4088/jcp.21m14345" @default.
• W4281570368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35649167" @default.
• W4281570368 hasPublicationYear "2022" @default.
• W4281570368 type Work @default.
• W4281570368 citedByCount "28" @default.
• W4281570368 countsByYear W42815703682022 @default.
• W4281570368 countsByYear W42815703682023 @default.
• W4281570368 crossrefType "journal-article" @default.
• W4281570368 hasAuthorship W4281570368A5009671318 @default.
• W4281570368 hasAuthorship W4281570368A5045156395 @default.
• W4281570368 hasAuthorship W4281570368A5048498728 @default.
• W4281570368 hasAuthorship W4281570368A5065878511 @default.
• W4281570368 hasAuthorship W4281570368A5073345392 @default.
• W4281570368 hasAuthorship W4281570368A5080797609 @default.
• W4281570368 hasAuthorship W4281570368A5084024326 @default.
• W4281570368 hasBestOaLocation W42815703681 @default.
• W4281570368 hasConcept C126322002 @default.
• W4281570368 hasConcept C142724271 @default.
• W4281570368 hasConcept C15744967 @default.
• W4281570368 hasConcept C168563851 @default.
• W4281570368 hasConcept C204787440 @default.
• W4281570368 hasConcept C27081682 @default.
• W4281570368 hasConcept C2777843972 @default.
• W4281570368 hasConcept C2779144063 @default.
• W4281570368 hasConcept C2779908668 @default.
• W4281570368 hasConcept C2780051608 @default.
• W4281570368 hasConcept C2781245242 @default.
• W4281570368 hasConcept C42219234 @default.
• W4281570368 hasConcept C71924100 @default.
• W4281570368 hasConceptScore W4281570368C126322002 @default.
• W4281570368 hasConceptScore W4281570368C142724271 @default.
• W4281570368 hasConceptScore W4281570368C15744967 @default.
• W4281570368 hasConceptScore W4281570368C168563851 @default.
• W4281570368 hasConceptScore W4281570368C204787440 @default.
• W4281570368 hasConceptScore W4281570368C27081682 @default.
• W4281570368 hasConceptScore W4281570368C2777843972 @default.
• W4281570368 hasConceptScore W4281570368C2779144063 @default.
• W4281570368 hasConceptScore W4281570368C2779908668 @default.
• W4281570368 hasConceptScore W4281570368C2780051608 @default.
• W4281570368 hasConceptScore W4281570368C2781245242 @default.
• W4281570368 hasConceptScore W4281570368C42219234 @default.
• W4281570368 hasConceptScore W4281570368C71924100 @default.
• W4281570368 hasIssue "4" @default.
• W4281570368 hasLocation W42815703681 @default.
• W4281570368 hasLocation W42815703682 @default.
• W4281570368 hasOpenAccess W4281570368 @default.
• W4281570368 hasPrimaryLocation W42815703681 @default.
• W4281570368 hasRelatedWork W2748952813 @default.
• W4281570368 hasRelatedWork W2899084033 @default.
• W4281570368 hasRelatedWork W3134298422 @default.
• W4281570368 hasRelatedWork W3170262232 @default.
• W4281570368 hasRelatedWork W4280521929 @default.
• W4281570368 hasRelatedWork W4281570368 @default.
• W4281570368 hasRelatedWork W4289520199 @default.
• W4281570368 hasRelatedWork W4307426720 @default.
• W4281570368 hasRelatedWork W4328049775 @default.
• W4281570368 hasRelatedWork W4383375041 @default.
• W4281570368 hasVolume "83" @default.
• W4281570368 isParatext "false" @default.
• W4281570368 isRetracted "false" @default.
• W4281570368 workType "article" @default.